NASDAQ:NKTR - Nektar Therapeutics Stock Price, Price Target & More

$84.51 -0.94 (-1.10 %)
(As of 04/24/2018 04:00 PM ET)
Previous Close$84.51
Today's Range$83.06 - $87.00
52-Week Range$17.33 - $111.36
Volume2.02 million shs
Average Volume3.04 million shs
Market Capitalization$13.87 billion
P/E Ratio-153.65
Dividend YieldN/A
Beta1.73

About Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics logoNektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain based on its PEGylation and polymer conjugate technology platforms in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreements with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, and Bristol-Myers Squibb Company. The company was founded in 1990 and is headquartered in San Francisco, California.

Receive NKTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:NKTR
CUSIP64026810
Phone415-482-5300

Debt

Debt-to-Equity Ratio2.79%
Current Ratio5.82%
Quick Ratio5.63%

Price-To-Earnings

Trailing P/E Ratio-153.65
Forward P/E Ratio-59.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$30.71 million
Price / Sales442.83
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book150.91

Profitability

EPS (Most Recent Fiscal Year)($0.55)
Net Income$-96,690,000.00
Net Margins-31.42%
Return on Equity-156.85%
Return on Assets-16.48%

Miscellaneous

Employees509
Outstanding Shares160,920,000

How to Become a New Pot Stock Millionaire

Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions

What is Nektar Therapeutics' stock symbol?

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

How were Nektar Therapeutics' earnings last quarter?

Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings results on Thursday, March, 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.14. The biopharmaceutical company had revenue of $95.47 million for the quarter, compared to the consensus estimate of $36.96 million. Nektar Therapeutics had a negative net margin of 31.42% and a negative return on equity of 156.85%. The company's revenue for the quarter was up 154.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.28) earnings per share. View Nektar Therapeutics' Earnings History.

When is Nektar Therapeutics' next earnings date?

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Nektar Therapeutics.

What price target have analysts set for NKTR?

13 equities research analysts have issued 12-month price objectives for Nektar Therapeutics' stock. Their predictions range from $20.00 to $125.00. On average, they anticipate Nektar Therapeutics' stock price to reach $79.75 in the next twelve months. View Analyst Ratings for Nektar Therapeutics.

What are Wall Street analysts saying about Nektar Therapeutics stock?

Here are some recent quotes from research analysts about Nektar Therapeutics stock:
  • 1. Mizuho analysts commented, "We believe Keytruda’s data reinforces our thesis on Nektar. Assuming positive data at ASCO, we believe BMS would be inclined to make a bid for Nektar given its deteriorating market position relative to Merck." (4/17/2018)
  • 2. According to Zacks Investment Research, "Nektar has a promising pipeline, with several updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik under the license agreement with AstraZeneca. Also, its recent codevelopment deal with Lilly for NKTR-358 is encouraging. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Moreover, competition from various pharmaceutical and biotechnology companies is another matter of concern. Shares of the company have significantly outperformed the industry in the last one year." (2/21/2018)

Who are some of Nektar Therapeutics' key competitors?

Who are Nektar Therapeutics' key executives?

Nektar Therapeutics' management team includes the folowing people:
  • Mr. Howard W. Robin, CEO, Pres & Director (Age 65)
  • Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 46)
  • Mr. John Nicholson, Sr. VP & COO (Age 66)
  • Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. and Chief Technical Operations Officer (Age 64)
  • Ms. Jillian B. Thomsen, Sr. VP of Fin. & Chief Accounting Officer (Age 52)

Has Nektar Therapeutics been receiving favorable news coverage?

News articles about NKTR stock have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nektar Therapeutics earned a news sentiment score of 0.04 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.36 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Nektar Therapeutics' major shareholders?

Nektar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (12.28%) and FMR LLC (12.28%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.

How do I buy shares of Nektar Therapeutics?

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nektar Therapeutics' stock price today?

One share of NKTR stock can currently be purchased for approximately $84.51.

How big of a company is Nektar Therapeutics?

Nektar Therapeutics has a market capitalization of $13.87 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.

How can I contact Nektar Therapeutics?

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]


MarketBeat Community Rating for Nektar Therapeutics (NKTR)

Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  403 (Vote Outperform)
Underperform Votes:  181 (Vote Underperform)
Total Votes:  584
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nektar Therapeutics (NASDAQ:NKTR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Nektar Therapeutics in the last 12 months. Their average twelve-month price target is $79.75, suggesting that the stock has a possible downside of 5.63%. The high price target for NKTR is $125.00 and the low price target for NKTR is $20.00. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.922.922.90
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $79.75$57.5455$48.1818$27.1111
Price Target Upside: 5.63% downside44.06% downside32.70% downside18.23% upside

Nektar Therapeutics (NASDAQ:NKTR) Consensus Price Target History

Price Target History for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/20/2018Seaport Global SecuritiesInitiated CoverageBuy$120.00LowView Rating Details
4/17/2018HC WainwrightSet Price TargetBuy$125.00LowView Rating Details
4/17/2018MizuhoReiterated RatingBuy$103.00LowView Rating Details
4/13/2018Piper JaffrayInitiated CoverageOverweight -> Overweight$125.00MediumView Rating Details
3/2/2018CowenReiterated RatingBuy$101.00LowView Rating Details
3/2/2018Jefferies GroupBoost Price TargetBuy$103.00HighView Rating Details
3/2/2018Canaccord GenuityBoost Price TargetBuy -> Buy$94.00HighView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$45.00N/AView Rating Details
11/13/2017JPMorgan ChaseReiterated RatingPositive -> Buy$44.00N/AView Rating Details
8/17/2017Evercore ISIInitiated CoverageIn -> In-Line$20.00HighView Rating Details
7/18/2017William BlairReiterated RatingOutperformLowView Rating Details
5/10/2017AegisReiterated RatingBuy$27.00HighView Rating Details
3/21/2017BTIG ResearchBoost Price TargetPositive$22.00 -> $27.00MediumView Rating Details
9/30/2016Brean CapitalReiterated RatingBuy$23.00N/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Nektar Therapeutics (NASDAQ:NKTR) Earnings History and Estimates Chart

Earnings by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) Earnings Estimates

2018 EPS Consensus Estimate: ($1.01)
2019 EPS Consensus Estimate: ($3.63)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.32)($0.12)($0.22)
Q2 20182($0.32)($0.13)($0.23)
Q3 20182($0.33)($0.13)($0.23)
Q4 20181($0.33)($0.33)($0.33)
Q1 20191($0.87)($0.87)($0.87)
Q2 20191($0.89)($0.89)($0.89)
Q3 20191($0.92)($0.92)($0.92)
Q4 20191($0.95)($0.95)($0.95)

Nektar Therapeutics (NASDAQ NKTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.27)N/AView Earnings Details
3/1/2018Q4 2017($0.35)($0.21)$36.96 million$95.47 millionViewListenView Earnings Details
11/7/2017Q3 2017$0.21$0.3740$126.50 million$152.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.35)($0.39)$33.64 million$34.60 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.40)($0.42)$29.43 million$24.73 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.28)$40.83 million$37.45 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.32)$32.42 million$36.30 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.36)$34.17 million$32.77 millionViewListenView Earnings Details
5/3/2016Q1($0.23)($0.14)$43.78 million$58.88 millionViewN/AView Earnings Details
3/1/2016Q4($0.42)($0.40)$28.82 million$39.40 millionViewListenView Earnings Details
11/5/2015Q315($0.30)($0.06)$44.30 million$60.00 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.40)$21.49 million$22.66 millionViewN/AView Earnings Details
4/30/2015Q115($0.40)$0.25$20.20 million$108.80 millionViewN/AView Earnings Details
2/24/2015Q414($0.36)($0.35)$12.30 million$19.55 millionViewN/AView Earnings Details
11/6/2014Q314$0.39$0.53$123.20 million$132.90 millionViewN/AView Earnings Details
7/31/2014Q214($0.38)($0.26)$19.76 million$28.50 millionViewListenView Earnings Details
5/7/2014Q114($0.35)($0.37)$38.68 million$19.80 millionViewListenView Earnings Details
2/26/2014Q413($0.17)($0.41)$49.26 million$31.15 millionViewN/AView Earnings Details
11/7/2013Q313($0.22)($0.14)$54.34 million$60.91 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.44)($0.37)$26.22 million$33.86 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.48)$26.30 million$23.00 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.45)($0.46)ViewN/AView Earnings Details
11/9/2012Q312($0.39)($0.38)$21.02 million$18.41 millionViewN/AView Earnings Details
8/9/2012($0.33)($0.30)ViewN/AView Earnings Details
5/2/2012($0.33)($0.36)ViewN/AView Earnings Details
2/29/2012($0.47)($0.33)ViewN/AView Earnings Details
11/2/2011($0.37)($0.21)ViewN/AView Earnings Details
8/4/2011($0.31)($0.32)ViewN/AView Earnings Details
4/27/2011($0.27)($0.33)ViewN/AView Earnings Details
3/1/2011Q4 2010($0.16)($0.11)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.05)($0.09)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.09)($0.01)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.09)($0.07)ViewN/AView Earnings Details
3/2/2010Q4 2009$0.08($0.08)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.40)($0.33)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.42)($0.35)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.41)($0.34)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.31)($0.46)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.29)($0.40)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.31)($0.36)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.27)($0.44)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.25)($0.13)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Nektar Therapeutics (NASDAQ:NKTR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Nektar Therapeutics (NASDAQ NKTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.44%
Institutional Ownership Percentage: 96.31%
Insider Trading History for Nektar Therapeutics (NASDAQ:NKTR)
Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ NKTR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Jillian B. ThomsenSVPSell13,881$101.46$1,408,366.26View SEC Filing  
4/9/2018Stephen K DobersteinSVPSell160,000$93.06$14,889,600.00127,394View SEC Filing  
4/6/2018Robert ChessDirectorSell25,000$92.14$2,303,500.00284,223View SEC Filing  
4/5/2018Maninder HoraSVPSell20,000$101.75$2,035,000.00127,394View SEC Filing  
3/7/2018Christopher A KueblerDirectorSell40,000$97.60$3,904,000.0043,100View SEC Filing  
3/7/2018John NicholsonCOOSell220,144$99.27$21,853,694.88267,657View SEC Filing  
2/16/2018Gil M. LabrucherieCFOSell3,477$82.94$288,382.38View SEC Filing  
2/16/2018Howard W RobinCEOSell12,788$82.94$1,060,636.72237,147View SEC Filing  
2/16/2018Jillian B. ThomsenCAOSell2,545$82.94$211,082.30View SEC Filing  
2/16/2018John NicholsonCOOSell4,879$82.94$404,664.26387,657View SEC Filing  
2/16/2018Stephen K DobersteinSVPSell2,426$82.94$201,212.4467,394View SEC Filing  
1/22/2018Howard W RobinCEOSell83,333$75.82$6,318,308.06333,268View SEC Filing  
1/2/2018Christopher A KueblerDirectorSell30,000$58.66$1,759,800.0070,500View SEC Filing  
12/13/2017Howard W RobinCEOSell83,333$55.69$4,640,814.77272,768View SEC Filing  
11/13/2017John NicholsonCOOSell15,910$37.78$601,079.80249,066View SEC Filing  
11/8/2017Stephen K DobersteinSVPSell396,323$29.00$11,493,367.0052,016View SEC Filing  
11/6/2017Maninder HoraSVPSell5,117$25.07$128,283.1952,016View SEC Filing  
11/1/2017Howard W RobinCEOSell83,334$23.57$1,964,182.38235,838View SEC Filing  
10/9/2017Howard W RobinCEOSell83,333$24.20$2,016,658.60View SEC Filing  
10/5/2017Stephen K DobersteinSVPSell43,677$24.97$1,090,614.69View SEC Filing  
10/2/2017Gil M. LabrucherieCFOSell120,000$24.45$2,934,000.00View SEC Filing  
10/2/2017Ivan P GergelSVPSell100,000$24.14$2,414,000.0084,871View SEC Filing  
9/22/2017Christopher A KueblerDirectorSell4,000$21.86$87,440.0040,500View SEC Filing  
9/21/2017Robert ChessDirectorSell6,400$21.72$139,008.00274,223View SEC Filing  
9/6/2017Howard W RobinCEOSell83,333$21.54$1,794,992.82235,837View SEC Filing  
8/16/2017Howard W RobinCEOSell91,714$19.26$1,766,411.64152,504View SEC Filing  
8/16/2017Jillian B. ThomsenCAOSell2,648$19.32$51,159.36View SEC Filing  
8/16/2017John NicholsonCOOSell3,177$19.32$61,379.64224,066View SEC Filing  
8/16/2017Stephen K DobersteinSVPSell1,701$19.32$32,863.3231,102View SEC Filing  
8/10/2017Roy A WhitfieldDirectorBuy35,000$17.95$628,250.00133,000View SEC Filing  
7/18/2017Ivan P GergelSVPSell54,920$21.10$1,158,812.0098,492View SEC Filing  
7/14/2017Lutz LingnauDirectorSell30,000$20.76$622,800.0053,450View SEC Filing  
7/12/2017Ivan P GergelSVPSell45,080$21.08$950,286.4051,961View SEC Filing  
7/11/2017Ivan P GergelSVPSell8,389$21.04$176,504.5651,961View SEC Filing  
5/16/2017Gil M. LabrucherieCFOSell3,179$19.55$62,149.45View SEC Filing  
5/16/2017Howard W RobinCEOSell8,388$19.55$163,985.40160,884View SEC Filing  
5/16/2017John NicholsonCOOSell3,146$19.55$61,504.30178,943View SEC Filing  
5/16/2017Stephen K DobersteinSVPSell1,701$19.55$33,254.5532,803View SEC Filing  
5/15/2017Robert ChessDirectorSell5,000$19.79$98,950.00276,623View SEC Filing  
4/17/2017Robert ChessDirectorSell5,000$18.72$93,600.00276,623View SEC Filing  
4/7/2017Lutz LingnauDirectorSell7,000$20.05$140,350.0023,450View SEC Filing  
4/5/2017Christopher A KueblerDirectorSell15,000$21.88$328,200.0050,500View SEC Filing  
4/5/2017Maninder HoraSVPSell180,000$21.70$3,906,000.00View SEC Filing  
3/20/2017Jillian B. ThomsenSVPSell112,500$19.69$2,215,125.00View SEC Filing  
3/3/2017Gil M. LabrucherieCFOSell200,000$15.16$3,032,000.00View SEC Filing  
2/16/2017Gil M. LabrucherieCFOSell2,359$13.14$30,997.26View SEC Filing  
2/16/2017Howard W RobinCEOSell8,636$13.14$113,477.04169,272View SEC Filing  
2/16/2017Ivan P GergelSVPSell1,457$13.14$19,144.9845,022View SEC Filing  
2/16/2017John NicholsonCOOSell3,237$13.14$42,534.18182,089View SEC Filing  
2/8/2017Howard W RobinCEOSell87,500$13.04$1,141,000.00265,408View SEC Filing  
2/3/2017John NicholsonCOOSell75,000$12.39$929,250.00206,821View SEC Filing  
1/17/2017Howard W RobinCEOSell87,500$12.35$1,080,625.00265,408View SEC Filing  
11/17/2016Howard W RobinCEOSell93,458$13.88$1,297,197.04122,908View SEC Filing  
10/24/2016R Scott GreerDirectorBuy15,000$13.50$202,500.00121,333View SEC Filing  
10/4/2016Howard W. RobinCEOSell87,500$17.06$1,492,750.00View SEC Filing  
9/16/2016Christopher A. KueblerDirectorSell7,500$19.13$143,475.00View SEC Filing  
9/15/2016Robert ChessDirectorSell12,000$19.21$230,520.00View SEC Filing  
9/1/2016Howard W. RobinCEOSell87,500$17.83$1,560,125.00View SEC Filing  
8/16/2016Gil M. LabrucherieCFOSell3,305$17.56$58,035.80View SEC Filing  
8/16/2016Howard W. RobinCEOSell11,817$17.56$207,506.52View SEC Filing  
8/16/2016John NicholsonCOOSell3,317$17.56$58,246.52View SEC Filing  
8/16/2016Stephen K. DobersteinSVPSell1,336$17.56$23,460.16View SEC Filing  
8/1/2016Robert ChessDirectorSell5,000$17.26$86,300.00View SEC Filing  
7/11/2016Jillian B ThomsenCAOSell100,000$15.09$1,509,000.00106,809View SEC Filing  
7/1/2016Robert ChessDirectorSell5,000$14.10$70,500.00View SEC Filing  
5/17/2016Gil M LabrucherieSVPSell836$13.58$11,352.888,757View SEC Filing  
5/17/2016Howard W RobinCEOSell2,170$13.58$29,468.6019,103View SEC Filing  
5/17/2016Jillian B ThomsenCAOSell724$13.58$9,831.927,033View SEC Filing  
5/17/2016John NicholsonCFOSell856$13.58$11,624.4878,486View SEC Filing  
4/25/2016Lutz LingnauDirectorSell15,000$16.27$244,050.0031,450View SEC Filing  
2/17/2016Howard W. RobinCEOSell2,147$11.92$25,592.2413,478View SEC Filing  
2/17/2016Jillian B. ThomsenCAOSell716$11.92$8,534.725,158View SEC Filing  
2/17/2016Maninder HoraSVPSell963$11.92$11,478.965,803View SEC Filing  
2/10/2016Gil M. LabrucherieSVPSell11,666$11.49$134,042.345,251View SEC Filing  
2/10/2016Howard W. RobinCEOSell66,666$11.49$765,992.3410,000View SEC Filing  
2/10/2016Jillian B. ThomsenCAOSell15,000$11.49$172,350.003,999View SEC Filing  
1/20/2016Lutz LingnauDirectorSell15,000$14.51$217,650.0016,450View SEC Filing  
1/19/2016Gil M. LabrucherieSVPSell11,667$14.12$164,738.045,251View SEC Filing  
1/19/2016Howard W. RobinCEOSell66,667$14.12$941,338.0410,000View SEC Filing  
1/19/2016Jillian B. ThomsenCAOSell15,000$14.12$211,800.003,999View SEC Filing  
12/4/2015Christopher A. KueblerDirectorSell15,000$15.82$237,300.0020,000View SEC Filing  
12/3/2015Gil M. LabrucherieSVPSell45,001$15.87$714,165.875,251View SEC Filing  
12/3/2015Howard W. RobinCEOSell125,001$15.87$1,983,765.8710,000View SEC Filing  
12/3/2015Jillian B. ThomsenCAOSell15,000$15.87$238,050.003,999View SEC Filing  
11/20/2015Susan WangDirectorSell85,000$15.02$1,276,700.0020,000View SEC Filing  
11/11/2015Gil M. LabrucherieSVPSell45,000$13.52$608,400.004,751View SEC Filing  
11/11/2015Howard W. RobinCEOSell125,000$13.52$1,690,000.0010,000View SEC Filing  
11/11/2015Jillian B. ThomsenCAOSell15,000$13.52$202,800.003,499View SEC Filing  
10/28/2015Lutz LingnauDirectorSell12,500$12.00$150,000.0016,450View SEC Filing  
10/6/2015Gil M. LabrucherieSVPSell45,000$10.99$494,550.004,751View SEC Filing  
10/6/2015Howard W. RobinCEOSell125,000$10.99$1,373,750.0010,000View SEC Filing  
10/6/2015Jillian B. ThomsenCAOSell15,000$10.99$164,850.003,499View SEC Filing  
9/23/2015Gil M. LabrucherieSVPSell44,999$13.04$586,786.964,751View SEC Filing  
9/23/2015Howard W. RobinCEOSell124,999$13.04$1,629,986.9610,000View SEC Filing  
9/23/2015Jillian B. ThomsenCAOSell10,000$13.04$130,400.003,499View SEC Filing  
8/13/2015Gil M LabrucherieSVPSell33,333$10.89$362,996.37View SEC Filing  
8/13/2015Howard W RobinCEOSell58,333$10.89$635,246.37View SEC Filing  
7/14/2015Gil M LabrucherieSVPSell33,334$11.78$392,674.52View SEC Filing  
7/14/2015Howard W RobinCEOSell58,334$11.78$687,174.52View SEC Filing  
6/29/2015Susan WangDirectorSell30,000$12.70$381,000.00View SEC Filing  
6/19/2015Robert ChessDirectorSell15,000$11.81$177,150.00View SEC Filing  
6/15/2015Lutz LingnauDirectorSell25,000$11.15$278,750.00View SEC Filing  
12/29/2014Robert ChessDirectorSell29,500$15.34$452,530.00View SEC Filing  
12/22/2014Jillian B ThomsenCAOSell5,000$15.56$77,800.00View SEC Filing  
12/1/2014Gil M LabrucherieSVPSell120,000$17.02$2,042,400.00View SEC Filing  
12/1/2014Howard W RobinCEOSell350,000$17.01$5,953,500.00View SEC Filing  
11/25/2014Howard W RobinCEOSell600,000$15.25$9,150,000.00View SEC Filing  
11/24/2014Gil M LabrucherieSVPSell10,500$15.04$157,920.00View SEC Filing  
11/24/2014Howard W RobinCEOSell132,800$15.02$1,994,656.00View SEC Filing  
11/24/2014Lutz LingnauDirectorSell15,000$15.02$225,300.00View SEC Filing  
11/3/2014Gil M LabrucherieSVPSell9,900$13.78$136,422.00View SEC Filing  
8/5/2013Roy WhitfieldDirectorSell12,500$12.41$155,125.0020,000View SEC Filing  
9/14/2012Dennis L WingerDirectorBuy5,000$9.18$45,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nektar Therapeutics (NASDAQ NKTR) News Headlines

Source:
DateHeadline
Nektar Enters Into New Clinical Collaboration With TakedaNektar Enters Into New Clinical Collaboration With Takeda
www.nasdaq.com - April 24 at 10:28 AM
BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid TumorsBRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors
www.reuters.com - April 24 at 10:28 AM
Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?Should Vanguard S&P Small-Cap 600 Growth ETF (VIOG) Be on Your Investing Radar?
finance.yahoo.com - April 24 at 10:28 AM
 Analysts Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $49.67 Million Analysts Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $49.67 Million
www.americanbankingnews.com - April 21 at 5:34 AM
Nektar Therapeutics (NKTR) Now Covered by Seaport Global SecuritiesNektar Therapeutics (NKTR) Now Covered by Seaport Global Securities
www.americanbankingnews.com - April 20 at 11:54 AM
 Brokerages Anticipate Nektar Therapeutics (NKTR) Will Announce Earnings of -$0.45 Per Share Brokerages Anticipate Nektar Therapeutics (NKTR) Will Announce Earnings of -$0.45 Per Share
www.americanbankingnews.com - April 19 at 3:24 AM
Nektar Therapeutics (NKTR) SVP Jillian B. Thomsen Sells 13,881 SharesNektar Therapeutics (NKTR) SVP Jillian B. Thomsen Sells 13,881 Shares
www.americanbankingnews.com - April 18 at 7:13 PM
Nektar Therapeutics (NKTR) Cut to Buy at BidaskClubNektar Therapeutics (NKTR) Cut to Buy at BidaskClub
www.americanbankingnews.com - April 18 at 9:51 AM
Nektar Therapeutics (NKTR) Given a $125.00 Price Target by HC Wainwright AnalystsNektar Therapeutics (NKTR) Given a $125.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 18 at 8:40 AM
Nektar Therapeutics (NKTR) Announces New Preclinical Data on NKTR-214 and NKTR-262 at 2018 AACR MeetingsNektar Therapeutics (NKTR) Announces New Preclinical Data on NKTR-214 and NKTR-262 at 2018 AACR Meetings
www.streetinsider.com - April 17 at 10:43 AM
Today’s Research Reports on Stocks to Watch: Nektar Therapeutics and Merck & Co.Today’s Research Reports on Stocks to Watch: Nektar Therapeutics and Merck & Co.
finance.yahoo.com - April 17 at 10:43 AM
Nektar Therapeutics (NKTR) "Buy" Rating Reiterated at MizuhoNektar Therapeutics' (NKTR) "Buy" Rating Reiterated at Mizuho
www.americanbankingnews.com - April 17 at 8:17 AM
Nektar Therapeutics (NKTR) Receives Outperform Rating from William BlairNektar Therapeutics (NKTR) Receives Outperform Rating from William Blair
www.americanbankingnews.com - April 17 at 12:04 AM
Today’s Research Reports on Trending Tickers: Valeant Pharmaceuticals and Nektar TherapeuticsToday’s Research Reports on Trending Tickers: Valeant Pharmaceuticals and Nektar Therapeutics
finance.yahoo.com - April 16 at 10:26 AM
Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018
www.prnewswire.com - April 15 at 6:13 PM
Nektar Therapeutics: What The REVEAL Study EntailsNektar Therapeutics: What The REVEAL Study Entails
seekingalpha.com - April 13 at 10:58 AM
Nektar Therapeutics (NKTR) Reports Dosing of 1st Patient Phase 1/2 Clinical ...Nektar Therapeutics (NKTR) Reports Dosing of 1st Patient Phase 1/2 Clinical ...
www.streetinsider.com - April 13 at 10:58 AM
Nektar Therapeutics (NKTR) Earns Buy Rating from Analysts at Piper JaffrayNektar Therapeutics (NKTR) Earns Buy Rating from Analysts at Piper Jaffray
www.americanbankingnews.com - April 13 at 10:13 AM
Nektar Therapeutics (NKTR) Now Covered by HC WainwrightNektar Therapeutics (NKTR) Now Covered by HC Wainwright
www.americanbankingnews.com - April 13 at 12:58 AM
NKTR June 1st Options Begin TradingNKTR June 1st Options Begin Trading
www.nasdaq.com - April 12 at 11:32 AM
Nektar Starts Phase I/II Combo for Advanced Solid TumorsNektar Starts Phase I/II Combo for Advanced Solid Tumors
finance.yahoo.com - April 12 at 11:32 AM
Nektar Therapeutics (NKTR) Receives Average Recommendation of "Buy" from AnalystsNektar Therapeutics (NKTR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 9:13 AM
Nektar commences Phase 1/2 study of NKTR/262/NKTR-214 combo in solid tumorsNektar commences Phase 1/2 study of NKTR/262/NKTR-214 combo in solid tumors
seekingalpha.com - April 11 at 3:38 PM
Why CASI Pharmaceuticals Stock Rose Last WeekWhy CASI Pharmaceuticals Stock Rose Last Week
finance.yahoo.com - April 11 at 3:38 PM
Nektar Therapeutics Begins Dosing Patients In Phase 1/2 REVEAL Clinical StudyNektar Therapeutics Begins Dosing Patients In Phase 1/2 REVEAL Clinical Study
www.nasdaq.com - April 11 at 11:15 AM
Roth Capital Analysts Give Nektar Therapeutics (NKTR) a $33.00 Price TargetRoth Capital Analysts Give Nektar Therapeutics (NKTR) a $33.00 Price Target
www.americanbankingnews.com - April 11 at 12:43 AM
NKTR Crosses Above Average Analyst TargetNKTR Crosses Above Average Analyst Target
www.nasdaq.com - April 10 at 10:54 AM
Today’s Research Reports on Trending Tickers: Clovis Oncology and Nektar TherapeuticsToday’s Research Reports on Trending Tickers: Clovis Oncology and Nektar Therapeutics
finance.yahoo.com - April 10 at 10:54 AM
Insider Selling: Nektar Therapeutics (NKTR) SVP Sells 160,000 Shares of StockInsider Selling: Nektar Therapeutics (NKTR) SVP Sells 160,000 Shares of Stock
www.americanbankingnews.com - April 9 at 10:26 PM
Nektar Therapeutics (NKTR) SVP Sells $2,035,000.00 in StockNektar Therapeutics (NKTR) SVP Sells $2,035,000.00 in Stock
www.americanbankingnews.com - April 9 at 10:26 PM
Nektar Therapeutics (NKTR) Director Sells $2,303,500.00 in StockNektar Therapeutics (NKTR) Director Sells $2,303,500.00 in Stock
www.americanbankingnews.com - April 9 at 10:26 PM
Nektar Therapeutics (NKTR) Rating Lowered to Sell at BidaskClubNektar Therapeutics (NKTR) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 9 at 10:19 PM
Nektar Therapeutics: Top Gainer from S&P 500 in 1Q18Nektar Therapeutics: Top Gainer from S&P 500 in 1Q18
finance.yahoo.com - April 9 at 3:37 PM
HC Wainwright Reiterates "$125.00" Price Target for Nektar Therapeutics (NKTR)HC Wainwright Reiterates "$125.00" Price Target for Nektar Therapeutics (NKTR)
www.americanbankingnews.com - April 9 at 8:25 AM
Heres Why Nektar Therapeutics Jumped 23% Higher in MarchHere's Why Nektar Therapeutics Jumped 23% Higher in March
www.msn.com - April 8 at 3:38 PM
Here's Why Nektar Therapeutics Jumped 23% Higher in MarchHere's Why Nektar Therapeutics Jumped 23% Higher in March
finance.yahoo.com - April 8 at 3:38 PM
Nektar Therapeutics (NKTR) PT Raised to $103 at Mizuho; Epacadostat Failure a PositiveNektar Therapeutics (NKTR) PT Raised to $103 at Mizuho; Epacadostat Failure a Positive
www.streetinsider.com - April 7 at 2:17 PM
These S&P Stocks Jumped 50% in the 1st QuarterThese S&P Stocks Jumped 50% in the 1st Quarter
finance.yahoo.com - April 7 at 2:17 PM
Friday Sector Laggards: Healthcare, IndustrialFriday Sector Laggards: Healthcare, Industrial
www.nasdaq.com - April 6 at 3:40 PM
Mizuho Raises Nektar Therapeutics (NKTR) Price Target to $103.00Mizuho Raises Nektar Therapeutics (NKTR) Price Target to $103.00
www.americanbankingnews.com - April 6 at 1:23 PM
BioSci Rounds Report: Unlocking Hidden Values In Omeros, Unum, And NektarBioSci Rounds Report: Unlocking Hidden Values In Omeros, Unum, And Nektar
seekingalpha.com - April 5 at 3:37 PM
Zacks: Brokerages Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $52.42 MillionZacks: Brokerages Expect Nektar Therapeutics (NKTR) Will Post Quarterly Sales of $52.42 Million
www.americanbankingnews.com - April 4 at 4:54 AM
Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers SquibbNektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb
www.prnewswire.com - April 3 at 5:58 PM
Analysts’ Recommendations for United Therapeutics in March 2018Analysts’ Recommendations for United Therapeutics in March 2018
finance.yahoo.com - April 3 at 10:55 AM
Nektar Therapeutics (NKTR) Buy Rating Reaffirmed at HC WainwrightNektar Therapeutics' (NKTR) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 2 at 9:04 AM
Zacks: Brokerages Anticipate Nektar Therapeutics (NKTR) to Announce -$0.43 Earnings Per ShareZacks: Brokerages Anticipate Nektar Therapeutics (NKTR) to Announce -$0.43 Earnings Per Share
www.americanbankingnews.com - April 2 at 3:20 AM
The S&P 500s Biggest Gainers And Losers In A Turbulent First QuarterThe S&P 500's Biggest Gainers And Losers In A Turbulent First Quarter
www.benzinga.com - April 1 at 3:40 PM
Nektar Therapeutics (NKTR) Rating Reiterated by Jefferies GroupNektar Therapeutics (NKTR) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 1 at 11:22 AM
Nektar Therapeutics (NKTR) Now Covered by Canaccord GenuityNektar Therapeutics (NKTR) Now Covered by Canaccord Genuity
www.americanbankingnews.com - March 31 at 8:16 PM
The S&P 500′s 10 Biggest Winners of the Quarter: Nektar SoarsThe S&P 500′s 10 Biggest Winners of the Quarter: Nektar Soars
finance.yahoo.com - March 30 at 10:47 AM

SEC Filings

Nektar Therapeutics (NASDAQ:NKTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nektar Therapeutics (NASDAQ:NKTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nektar Therapeutics (NASDAQ NKTR) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.